This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Hyaluronan-mediated motility receptor (RHAMM; CD168)	Human samples and mouse studies suggest inhibiting RHAMM could help treat glioblastoma. Analysis of human glioma samples revealed higher <i>RHAMM</i> expression than that in normal brain tissue. In mice bearing human glioblastoma cells, shRNA knockdown of <i>RHAMM</i> decreased tumor-forming potential compared with no alteration, whereas overexpression of <i>RHAMM</i> increased expression of stem cell markers and tumor growth. Next steps include testing the effects of chemical compounds that inhibit <i>RHAMM</i> expression in glioma stem cells.	Patent and licensing status undisclosed	Tilghman, J. <i>et al. Cancer Res.</i> ; published online April 7, 2014; doi:10.1158/0008-5472.CAN-13-2103 Contact: Mingyao Ying, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: ying@kennedykrieger.org
		<i>SciBX</i> 7(19); doi:10.1038/scibx.2014.552 Published online May 15, 2014		